Key Researchers at Stifel Nicolaus Maintained their ‘Buy’ rating for Boston Scientific Corp (NYSE:BSX) Shares Today. Their TP Given is $32.0

January 12, 2018 - By Migdalia James

 Key Researchers at Stifel Nicolaus Maintained their ‘Buy’ rating for Boston Scientific Corp (NYSE:BSX) Shares Today. Their TP Given is $32.0

Investors sentiment increased to 1.04 in 2017 Q3. Its up 0.01, from 1.03 in 2017Q2. It is positive, as 33 investors sold Boston Scientific Corporation shares while 166 reduced holdings. 43 funds opened positions while 164 raised stakes. 1.21 billion shares or 1.08% less from 1.22 billion shares in 2017Q2 were reported.

First Allied Advisory stated it has 7,127 shares. Advisor Limited Liability Corporation holds 0.15% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 26,937 shares. Reilly Advisors Limited Liability Com has invested 0% in Boston Scientific Corporation (NYSE:BSX). Royal Fincl Bank Of Canada has invested 0.01% of its portfolio in Boston Scientific Corporation (NYSE:BSX). 1.23M were reported by Pictet Asset. Ledyard Commercial Bank owns 390 shares. Product Prtn Ltd Co holds 852,200 shares or 0.82% of its portfolio. 28,244 were reported by Ajo Limited Partnership. Jennison Assocs Ltd Limited Liability Company reported 0.24% in Boston Scientific Corporation (NYSE:BSX). Metropolitan Life Communication Ny invested 0.13% in Boston Scientific Corporation (NYSE:BSX). 33,111 are held by Conning Incorporated. Deltec Asset Management Ltd Liability has invested 1.55% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Manchester Cap Mgmt Ltd accumulated 0.03% or 6,957 shares. Contravisory Management Inc accumulated 0% or 22 shares. Legal And General Public Lc holds 0.15% or 6.76M shares.

Since August 1, 2017, it had 0 buys, and 13 insider sales for $15.16 million activity. Nanavaty Maulik sold $1.56 million worth of stock or 57,031 shares. Pratt Timothy A. sold 10,000 shares worth $266,650. Bose Supratim sold $10.11 million worth of stock or 347,137 shares. $208,328 worth of Boston Scientific Corporation (NYSE:BSX) was sold by Sorenson John Bradley on Wednesday, August 2. $332,584 worth of Boston Scientific Corporation (NYSE:BSX) shares were sold by Carruthers Wendy. Phalen Michael P. sold $440,547 worth of stock or 15,500 shares.

Boston Scientific Corp (NYSE:BSX) Rating Reaffirmed

Equity analysts at Stifel Nicolaus now has a $32.0 price target on Boston Scientific Corp (NYSE:BSX). Stifel Nicolaus and their recent price target means a potential upside of 16.75 % from the company’s last stock price. The rating has been disclosed to clients in a research report on 26 October.

Investors sentiment increased to 1.04 in 2017 Q3. Its up 0.01, from 1.03 in 2017Q2. It is positive, as 33 investors sold Boston Scientific Corporation shares while 166 reduced holdings. 43 funds opened positions while 164 raised stakes. 1.21 billion shares or 1.08% less from 1.22 billion shares in 2017Q2 were reported.

First Allied Advisory stated it has 7,127 shares. Advisor Limited Liability Corporation holds 0.15% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 26,937 shares. Reilly Advisors Limited Liability Com has invested 0% in Boston Scientific Corporation (NYSE:BSX). Royal Fincl Bank Of Canada has invested 0.01% of its portfolio in Boston Scientific Corporation (NYSE:BSX). 1.23M were reported by Pictet Asset. Ledyard Commercial Bank owns 390 shares. Product Prtn Ltd Co holds 852,200 shares or 0.82% of its portfolio. 28,244 were reported by Ajo Limited Partnership. Jennison Assocs Ltd Limited Liability Company reported 0.24% in Boston Scientific Corporation (NYSE:BSX). Metropolitan Life Communication Ny invested 0.13% in Boston Scientific Corporation (NYSE:BSX). 33,111 are held by Conning Incorporated. Deltec Asset Management Ltd Liability has invested 1.55% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Manchester Cap Mgmt Ltd accumulated 0.03% or 6,957 shares. Contravisory Management Inc accumulated 0% or 22 shares. Legal And General Public Lc holds 0.15% or 6.76M shares.

Since August 1, 2017, it had 0 buys, and 13 insider sales for $15.16 million activity. Nanavaty Maulik sold $1.56 million worth of stock or 57,031 shares. Pratt Timothy A. sold 10,000 shares worth $266,650. Bose Supratim sold $10.11 million worth of stock or 347,137 shares. $208,328 worth of Boston Scientific Corporation (NYSE:BSX) was sold by Sorenson John Bradley on Wednesday, August 2. $332,584 worth of Boston Scientific Corporation (NYSE:BSX) shares were sold by Carruthers Wendy. Phalen Michael P. sold $440,547 worth of stock or 15,500 shares.

Boston Scientific Corporation (NYSE:BSX) Ratings Coverage

Among 29 analysts covering Boston Scientific Corporation (NYSE:BSX), 23 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. Boston Scientific Corporation has $36 highest and $19 lowest target. $28.48’s average target is 3.91% above currents $27.409 stock price. Boston Scientific Corporation had 83 analyst reports since July 27, 2015 according to SRatingsIntel. Jefferies maintained Boston Scientific Corporation (NYSE:BSX) on Tuesday, June 27 with “Hold” rating. The rating was initiated by Suntrust Robinson on Thursday, February 25 with “Buy”. The stock of Boston Scientific Corporation (NYSE:BSX) has “Buy” rating given on Friday, November 3 by Needham. Nomura initiated the shares of BSX in report on Thursday, March 17 with “Buy” rating. As per Friday, October 27, the company rating was maintained by BMO Capital Markets. The rating was maintained by Oppenheimer on Monday, May 1 with “Hold”. The rating was maintained by Jefferies with “Hold” on Friday, July 28. The firm has “Buy” rating given on Thursday, February 25 by SunTrust. The company was maintained on Sunday, November 5 by RBC Capital Markets. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Buy” rating by Needham on Thursday, October 26.

The stock decreased 0.08% or $0.021 during the last trading session, reaching $27.409. About 266,974 shares traded. Boston Scientific Corporation (NYSE:BSX) has risen 19.12% since January 12, 2017 and is uptrending. It has outperformed by 2.42% the S&P500.

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on February, 1. They expect $0.34 earnings per share, up 13.33 % or $0.04 from last year’s $0.3 per share. BSX’s profit will be $466.89M for 20.15 P/E if the $0.34 EPS becomes a reality. After $0.31 actual earnings per share reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts 9.68 % EPS growth.

Boston Scientific Corporation develops, makes, and markets medical devices for use in various interventional medical specialties worldwide. The company has market cap of $37.64 billion. It operates through three divisions: Cardiovascular, Rhythm Management, and MedSurg. It has a 44.93 P/E ratio. The firm offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; other coronary therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

More notable recent Boston Scientific Corporation (NYSE:BSX) news were published by: Seekingalpha.com which released: “Boston Scientific reports preliminary Q4 and FY17 sales” on January 09, 2018, also Zacks.com with their article: “Boston Scientific (BSX) Surges: Stock Moves 8.3% Higher January 10, 2018” published on January 10, 2018, Livetradingnews.com published: “Boston Scientific Corporation (NYSE:BSX) Bulls in Favor” on January 10, 2018. More interesting news about Boston Scientific Corporation (NYSE:BSX) were released by: Prnewswire.com and their article: “Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter …” published on January 09, 2018 as well as Prnewswire.com‘s news article titled: “Boston Scientific To Participate In 36th Annual JP Morgan Healthcare Conference” with publication date: December 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.